NCT04052971: To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors

NCT04052971
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 60 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, active, unstable CNS metastases and/or carcinomatous meningitis- see trial for details; Patients who had had prior treatment with more than 4 lines of systemic therapy for recurrent/metastatic disease
https://ClinicalTrials.gov/show/NCT04052971

Comments are closed.

Up ↑